PRMT1 and Miyoshi myopathy: Likewise, Jia et al. demonstrated that PRMT1 promotes MM tumorigenesis via WTAP methylation and downstream m6A modification of NDUFS6, thereby enhancing oxidative phosphorylation (OXPHOS), and further reported a synergistic effect when PRMT1 inhibition was combined with bortezomib [34].